Carregant...

Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update

Precision oncology is now the evidence-based standard of care for the management of many advanced non-small cell lung cancers (NSCLC). Notably, new molecular profiling technologies have permitted dynamic growth in the identification of actionable driver oncogenes including RET rearrangements. RET on...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncol Rev
Autor principal: Mendoza, Luis
Format: Artigo
Idioma:Inglês
Publicat: PAGEPress Publications, Pavia, Italy 2018
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6065052/
https://ncbi.nlm.nih.gov/pubmed/30093982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4081/oncol.2018.352
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!